SciSparc Ltd. (SPRC) is a clinical-stage pharmaceutical company based in Tel Aviv, Israel, focused on cannabinoid-based therapies. The stock has been one of the most volatile names on the Nasdaq Capital Market, trading between $2.98 and $80.10 over the past year. After a dramatic collapse from its highs, shares now hover near $6.66, which makes the round-number $10 stock price target a natural focal point for speculative traders.
The $10 level matters for several reasons. First, it is a psychological milestone that tends to attract attention and order flow. Second, it is not an unprecedented level — SciSparc shares have traded far above $10 within the past year — so reaching it again would represent a partial recovery rather than a new record. That distinction makes the $10 price forecast more realistic than a return to prior highs.
SciSparc develops drugs based on cannabinoid molecules, with pipeline candidates including SCI-110 for Tourette syndrome and Alzheimer's-related agitation, SCI-160 for pain, and SCI-210 for autism spectrum disorder and status epilepticus. The company also markets CannAmide, an anti-inflammatory and chronic-pain solution, and has partnered with Clearmind Medicine (CMND) on MDMA-based treatments for post-traumatic stress disorder.
Despite this pipeline, SciSparc remains a micro-cap with only a few million dollars in market value, minimal revenue, and deeply negative earnings. The company is very much in the clinical and exploratory stage, meaning its stock price is driven far more by news flow, sentiment, and technical trading than by traditional valuation metrics.
Several factors could support a rally toward the $10 target. The most recent catalyst was the U.S. publication of a patent application covering MDMA combined with certain compounds for PTSD, anxiety, and eating disorders, developed in collaboration with Clearmind Medicine. This coincided with the FDA's final guidance on psychedelic drug development, which explicitly includes MDMA and provides a clearer regulatory pathway for the collaboration's work.
Beyond the pipeline, SciSparc's extreme volatility cuts both ways. A stock with a beta above 2.0 that has already moved from single digits to $80 and back can, in theory, stage sharp rallies on relatively modest news or speculative buying. The very small float can amplify upward moves when demand increases. For traders, the market outlook for SPRC is therefore less about steady appreciation and more about the potential for sudden, news-driven spikes.
The obstacles are substantial. SciSparc generates negligible revenue and has a history of shareholder dilution, which weighs on the share price over time. The stock has repeatedly failed to sustain gains above the mid-single-digit range in recent months, and its long-term trend structure remains deeply damaged — shares are down roughly 90% from their 52-week high.
Wall Street coverage is also thin and skeptical. The limited analyst commentary that exists carries a "Sell" tone, and there is no established analyst price target that endorses a $10 objective. Without institutional support, meaningful clinical data, or a commercial breakthrough, the burden falls entirely on speculative retail demand to lift the stock.
From a technical analysis perspective, $10 represents a clear psychological resistance level. Below it, the 52-week low near $2.98 is the most important support level, and the stock has spent much of 2026 consolidating between roughly $4 and $8. A sustained break above the upper end of that range would be a necessary first step before the $10 level becomes a realistic near-term objective. Until then, the $10 mark functions primarily as a supply area where prior buyers may look to sell.
There is no credible analyst consensus supporting a $10 target for SciSparc. The company's valuation cannot be justified by earnings or revenue, and its appeal rests almost entirely on speculative potential in the cannabinoid and psychedelic spaces. Investors should treat any price forecast for SPRC as highly uncertain and understand that the company will likely require additional capital, which could pressure shares further even as the pipeline advances.
For traders seeking to monitor fast-moving, low-liquidity names like SciSparc, Tickeron's AI Daily Buy/Sell Signals offer an AI-driven tool that continuously scans thousands of stocks and ETFs to generate Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and automated analysis. These signals can help traders discover emerging opportunities, track existing positions, and identify changing trends more efficiently than manual chart review. Exploring AI Daily Buy/Sell Signals may provide useful context for timing decisions around volatile micro-caps.
A move to $10 for SciSparc is plausible in the sense that the stock has already traded far above that level within the past year and remains extremely volatile. The strongest arguments in favor of the move are the company's expanding patent portfolio, the FDA's psychedelic guidance, and the potential for sharp, sentiment-driven rallies in a thin float. The primary risks are equally clear: minimal revenue, ongoing dilution, a damaged long-term trend, and almost no supportive analyst coverage.
What should investors monitor going forward? Clinical and regulatory updates on the Clearmind collaboration, any signs of commercialization for CannAmide, changes in the company's capital structure, and whether the stock can establish a sustained base above its recent range. Without concrete catalysts, the $10 target is likely to remain more of a speculative aspiration than an imminent milestone.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, SPRC has been loosely correlated with GYRE. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if SPRC jumps, then GYRE could also see price increases.
| Ticker / NAME | Correlation To SPRC | 1D Price Change % | ||
|---|---|---|---|---|
| SPRC | 100% | +2.01% | ||
| GYRE - SPRC | 38% Loosely correlated | -0.15% | ||
| TBPH - SPRC | 36% Loosely correlated | -0.06% | ||
| MTNB - SPRC | 36% Loosely correlated | -9.76% | ||
| ALZN - SPRC | 31% Poorly correlated | +1.18% | ||
| NKTX - SPRC | 30% Poorly correlated | +3.56% | ||
More | ||||